anagliptin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Anagliptin is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".   Wikipedia

Chemistry

  • SMILES: Cl.Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N
  • InChIKey: SRIIFFBJIKZICS-RSAXXLAASA-N
  • Mol. Mass: 419.92
  • ALogP: 0.65
  • ChEMBL Molecule:
    anagliptin hydrochloride  
More Chemistry

Pharmacology

Alternative names

anagliptin | anagliptin hcl | anagliptin hydrochloride | beskoa | n-(2-((2-((2s)-2-cyanopyrrolidin-1-yl)-2-oxoethyl)amino)-2-methylpropyl)-2-methyl pyrazolo(1,5-a)pyrimidine-6-carboxamide hydrochloride | suiny

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Hyperglycemia

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Cholesterol, LDL (Phase 4)

Coronary Disease (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Dipeptidyl-Peptidase IV Inhibitors (Phase 4)

Glycated Hemoglobin (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue